{
    "nctId": "NCT00859703",
    "briefTitle": "Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer",
    "officialTitle": "Randomized, Double-blinded, Placebo Controlled Study to Assess Efficacy of Oral 35 mg Per Week Risedronate in Preventing Bone Loss in Postmenopausal Women With Aromatase Inhibitor Therapy for Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Menopause, Osteopenia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Evolution of the lumbar spine Bone Mineral Density after one year of treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women (more than one year since last menstrual period or removal of ovarian function by surgical or radiotherapic means)\n* Operated for an invasive breast cancer (histologically proven)\n* Surgical treatment completed and cycles of adjuvant chemotherapy (if necessary) completed\n* Treated with aromatase inhibitor\n* Osteopenic (-2.5\\<T score\\<-1) without osteoporotic fracture\n* With written informed consent signed\n* With social security\n\nExclusion Criteria:\n\n* Women presenting a history of osteoporotic fracture or a T score less than -2.5 at at least one measure site\n* Women presenting clinical signs of metastases\n* Having received other hormonal treatment in the last 3 months\n* Having received treatment by bisphosphonates, raloxifene, tamoxifen, parathormone, strontium ranelate, tibolone,calcitonin and corticosteroids at more than 5mg/d for 3 months in the last year\n* Presenting a known and untreated hyperthyroid\n* Presenting a known hyperadrenocorticism\n* Patients treated and followed for Paget's disease of bone\n* Presenting a untreated primary hyperparathyroid\n* Presenting an indication against risedronate (known hypersensibility to risedronate monosodium and/or one of its excipients, non-corrected hypocalcemia, pregnancy or breast feeding, severe renal insufficiency inferior to 30 ml/min)\n* Patients presenting malabsorption syndrome for glucose/galactose\n* Person participating in another clinical trial concerning a medicine susceptible to influence bone mass",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}